Ticker
ADIL

Price
0.57
Stock movement up
+0.02 (2.89%)
Company name
Adial Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
14.62M
Ent value
5.19M
Price/Sales
-
Price/Book
1.37
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-83.48%
3 year return
-28.81%
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ADIL does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book1.37
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count25.65M
EPS (TTM)-0.88
FCF per share (TTM)-0.59

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-17.51M
Net income (TTM)-17.50M
EPS (TTM)-0.88
EPS (1y forward)-0.59

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash12.69M
Net receivables0.00
Total current assets12.96M
Goodwill248.97K
Intangible assets4.90K
Property, plant and equipment0.00
Total assets13.96M
Accounts payable415.09K
Short/Current long term debt51.35K
Total current liabilities2.17M
Total liabilities3.26M
Shareholder's equity10.71M
Net tangible assets10.00M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-11.60M
Capital expenditures (TTM)98.33K
Free cash flow (TTM)-11.70M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-163.42%
Return on Assets-125.31%
Return on Invested Capital-162.64%
Cash Return on Invested Capital-108.76%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.54
Daily high0.59
Daily low0.54
Daily Volume142K
All-time high8.33
1y analyst estimate8.67
Beta0.74
EPS (TTM)-0.88
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ADILS&P500
Current price drop from All-time high-93.16%-13.41%
Highest price drop-93.35%-56.47%
Date of highest drop23 Aug 20229 Mar 2009
Avg drop from high-69.04%-11.38%
Avg time to new high93 days12 days
Max time to new high910 days1805 days
COMPANY DETAILS
ADIL (Adial Pharmaceuticals Inc) company logo
Marketcap
14.62M
Marketcap category
Small-cap
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Employees
16
Investor relations
-
SEC filings
CEO
William B. Stilley
Country
USA
City
Charlottesville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of t...
September 26, 2022
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic Constrictive Injury Model (Rat) CHARLOTTESVILLE, Va...
September 26, 2022
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary Purnovate Inc achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory ...
September 6, 2022
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) PNV-6005 - DSS-induced Ulcerative Colitis Mod...
September 6, 2022
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
September 1, 2022
Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises are part of Zacks Screen of the Week article.
August 29, 2022
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enter...
August 26, 2022
Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow CHARLOTTESVILLE, Va.,...
August 22, 2022
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Act...
August 16, 2022
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinki...
July 20, 2022
Next page